Pharmaceutical Intermediate Peptide Lab Supply Cjc-1295 With Dac 863288-34-0

Synonyms: CJC-1295 without DAC, CJC 1295 no DAC, , Neorelin, Modified Sermorelin
CAS NO.: 863288-34-0
Molecular Formula: C152H252N44O42
Molecular weight: 3367.2
Molar Mass: 3368.7
Peptide purity: > 98.0%
Appearance: White lyophilized powder
Related substance: Total Impurities (%) ≤ 2.0%
Acetate content: ≤ 15.0%
Bacterial Endotoxins: ≤5 IU/mg
Sequence: Tyr-d-ALA-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Source: Chemical Synthesis
Reconstitution: To follow best practice guidelines for reconstituting CJC-1295 without DAC, reconstitute in sterile, bacteriostatic, distilled water, with light sonication if necessary.
Shelf life: One year from dispatch.

Storage for CJC-1295 without DAC

Lyophilized MOD GRF 1-29 is stable at room temperature for 90 days, however it should be stored in a freezer below -8°C for any extended period of time. After reconstitution, may be stored for a maximum of 14 days in a refrigerator at 2°C - 8°C. Store vials in an upright position. Store MOD GRF-129 refrigerated between temperatures 2°C - 8°C. Keep in the outer carton in order to protect from light. For one month can be stored at room temperature.
 

Function & Usage

Modified GRF 1-29 is also known as Mod GRF 1-29, but even more commonly known as CJC-1295 without DAC. It is a protein that is 29 amino acids long and it is a GHRH analogue. CJC-1295 without DAC acts on receptors at the pituitary gland to stimulate the release of Human Growth Hormone.

CJC-1295 without DAC could be referred to more properly as a second generation derivative of GHRH. GHRH is modified to create what is known as Releasing Factor (GRF) 1-29, also known as Sermorelin. GRF 1-29 is then further modified to create Mod GRF 1-29 which is CJC-1295 without DAC.

CJC-1295 without DAC Dosage

Mod GRF 1-29 is typically provided in vials containing 2 mg of lyophylized powder, though the amount can vary. The contents should be reconstituted by adding a convenient amount of sterile or bacteriostatic water. If for example 2 mL is chosen and the dosing of the vial is 2 mg, the resulting solution then has a concentration of 1 mg/mL, or 1000 mcg/mL.

At time of dosing, an insulin syringe is used to draw and then inject the desired amount. In the above example, a 100 mcg dose would require a volume of 0.10 mL, or "10 IU" as marked on an insulin syringe.
Injection may be subcutaneous, intramuscular, or intravenous, according to personal preference. If desired, peptide solutions from other vials, such as a vial of a GHRP product, may also be drawn into the same syringe. This reduces the total number of injections required.